INT15746

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 1990
Last Reported 2008
Negated 2
Speculated 0
Reported most in Body
Documents 13
Total Number 17
Disease Relevance 6.45
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PDAP1) signal transduction (PDAP1)
Anatomy Link Frequency
lung 2
mitral valve 1
PDAP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Analgesic 1 89.68 High High
adenocard 15 89.12 High High
Dopamine 73 87.12 High High
Angina 7 81.92 Quite High
tolerance 7 72.20 Quite High
cva 55 70.20 Quite High
agonist 13 57.92 Quite High
Catecholamine 13 53.68 Quite High
anesthesia 13 53.64 Quite High
withdrawal 10 47.04 Quite Low
Disease Link Frequency Relevance Heat
Pulmonary Alveolar Proteinosis 49 100.00 Very High Very High Very High
Hypoxia 91 99.32 Very High Very High Very High
Pulmonary Hypertension 945 99.18 Very High Very High Very High
Increased Venous Pressure Under Development 154 98.60 Very High Very High Very High
Heart Rate Under Development 30 98.60 Very High Very High Very High
Cv General 4 Under Development 75 96.68 Very High Very High Very High
Adult Respiratory Distress Syndrome 120 96.60 Very High Very High Very High
Disease 16 91.88 High High
Hypertension 42 91.84 High High
Lung Injury 5 90.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Subthreshold doses (which do not reduce PAP) of specific phosphodiesterase-5 inhibitors (zaprinast and sildenafil) when used in acute lung injury (ALI) associated with pulmonary hypertension improved responsiveness to NO (Klein et al 2007).
Neg (not) Negative_regulation (reduce) of PAP in lung associated with pulmonary hypertension and adult respiratory distress syndrome
1) Confidence 0.52 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 1.13 Pain Relevance 0
Inhaled NO (INO) is a potent vasodilator that dilates pulmonary vasculature in ventilated lung areas, thereby improving V/Q match and oxygenation, and reducing PAP (Pepke-Zaba et al 1991) and RV oxygen demand (Zwissler et al 1995).
Negative_regulation (reducing) of PAP in lung
2) Confidence 0.52 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.46 Pain Relevance 0.05
RV dysfunction occurred with volume expansion, despite constant PVR and a decrease in mean PAP.
Negative_regulation (decrease) of PAP
3) Confidence 0.45 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.65 Pain Relevance 0.04
Inhaled nitroglycerin may be a safer therapeutic option leading to a significant reduction in both mean PAP and PVR in patients after mitral valve operations without reducing systemic mean arterial pressure (Yurtseven et al 2003).
Negative_regulation (reduction) of PAP in mitral valve
4) Confidence 0.45 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.87 Pain Relevance 0.08
Metabolism of PAP was extensive in all four species, and there were marked quantitative differences in the routes of metabolism.
Negative_regulation (Metabolism) of PAP
5) Confidence 0.43 Published 1990 Journal J Pharm Sci Section Abstract Doc Link 2352143 Disease Relevance 0 Pain Relevance 0.09
In animals with acute pulmonary hypertension administration of isoproterenol did not reduce PAP, and instead produced significant tachycardia and was associated with arrhythmias (Prielipp et al 1991).
Neg (not) Negative_regulation (reduce) of PAP associated with heart rate under development and pulmonary hypertension
6) Confidence 0.38 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.91 Pain Relevance 0.03
Aerosolized iloprost resulted in a more pronounced decrease in mean pulmonary arterial pressure (PAP) than sildenafil alone (9.4+/-1.3 versus 6.4+/-1.1 mm Hg; P<0.05).
Negative_regulation (decrease) of PAP
7) Confidence 0.25 Published 2001 Journal Circulation Section Body Doc Link 11551870 Disease Relevance 0 Pain Relevance 0
CONCLUSIONS: Sildenafil caused a long-lasting reduction in mean PAP and pulmonary vascular resistance, with a further additional improvement after iloprost inhalation.
Negative_regulation (reduction) of PAP
8) Confidence 0.25 Published 2001 Journal Circulation Section Body Doc Link 11551870 Disease Relevance 0 Pain Relevance 0
At individually highest comparable work loads mean PAP was reduced by 37% (p less than 0.001), and at maximal work load the PAP reduction was 14% (p less than 0.05).
Negative_regulation (reduction) of PAP
9) Confidence 0.24 Published 1991 Journal Cardiology Section Abstract Doc Link 1760835 Disease Relevance 0.23 Pain Relevance 0.19
At individually highest comparable work loads mean PAP was reduced by 28% (p less than 0.01), and at maximal work load the PAP reduction was 21% (p less than 0.05).
Negative_regulation (reduced) of PAP
10) Confidence 0.24 Published 1990 Journal Am. J. Cardiol. Section Abstract Doc Link 2349913 Disease Relevance 0.24 Pain Relevance 0.12
At individually highest comparable work loads mean PAP was reduced by 28% (p less than 0.01), and at maximal work load the PAP reduction was 21% (p less than 0.05).
Negative_regulation (reduction) of PAP
11) Confidence 0.24 Published 1990 Journal Am. J. Cardiol. Section Abstract Doc Link 2349913 Disease Relevance 0.23 Pain Relevance 0.11
At individually highest comparable work loads mean PAP was reduced by 37% (p less than 0.001), and at maximal work load the PAP reduction was 14% (p less than 0.05).
Negative_regulation (reduced) of PAP
12) Confidence 0.24 Published 1991 Journal Cardiology Section Abstract Doc Link 1760835 Disease Relevance 0.24 Pain Relevance 0.19
The combination of sildenafil plus iloprost lowered mean PAP significantly more than iloprost alone (13.8+/-1.4 versus 9.4+/-1.3 mm Hg; P<0.009).
Negative_regulation (lowered) of PAP
13) Confidence 0.22 Published 2001 Journal Circulation Section Body Doc Link 11551870 Disease Relevance 0 Pain Relevance 0
The reduction in mean PAP after sildenafil was maximal after the first dose (25 mg).
Negative_regulation (reduction) of PAP
14) Confidence 0.22 Published 2001 Journal Circulation Section Body Doc Link 11551870 Disease Relevance 0 Pain Relevance 0
In the presence of a lowered SAP/PAP ratio, owing to hypoxic pulmonary vasoconstriction, epinephrine did not alter the ratio but did increase cardiac output and therefore oxygen delivery.
Negative_regulation (lowered) of PAP associated with hypoxia and increased venous pressure under development
15) Confidence 0.21 Published 2001 Journal Crit Care Section Body Doc Link PMC31580 Disease Relevance 0.41 Pain Relevance 0.19
There is no evidence on the effectiveness of GM-CSF replacement for this condition: furthermore, it does not seem that GM-CSF signalling is impaired in PAP complicating LPI, thus suggesting a lack of rationale for substitutive treatment.
Negative_regulation (impaired) of PAP associated with pulmonary alveolar proteinosis
16) Confidence 0.15 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC1845139 Disease Relevance 1.03 Pain Relevance 0
Although BEL is a relatively selective PLA2 inhibitor at the concentration used, it has also been shown to inhibit Mg++-dependent phosphatidic acid phosphohydrolase (PAP-1), an enzyme that catalyzes the dephosphorylation of phosphatidic acid to diacylglycerol [30].
Negative_regulation (inhibit) of PAP-1
17) Confidence 0.02 Published 2007 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1868772 Disease Relevance 0.06 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox